Complex study delays BMS’ decision on Galecto takeover

2016 will not be the year when Denmark’s Galecto learns whether or not Bristol-Myers Squibb will buy the biotech in a multi-million-dollar deal. CEO Hans Schambye has a good gut feeling, however, nothing is set in stone in the world of biotech.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles